The Opportunity
The Ophthalmic drug industry grosses over $1.8 billion Canadian annually and is the fastest growing segment of the Canadian pharmaceutical industry. Genix's plan in the future is to research ocular herbal products and acquire an additional 70-100 ophthalmic drug products over the next 3 years.
Positioned For Growth
- Increasing incidence of eye diseases among all ages.
- Ophthalmic drugs patent cliff of $3B in next five years providing a significant growth opportunity for generic versions.
- Canadian ophthalmic segment has a 32.6% annual growth rate.
- Acquiring additional 70-100 ophthalmic drug products over the next 3 years.
Competitive Advantage
- Global market opportunity for generic ophthalmics exports
- Only four drug companies controlling the Canadian ophthalmics market
- Canadian ophthalmic drugs among the highest priced in the world
- Ophthalmic drugs have accelerated registration approvals as they do not require BA/BE studies to be done
Positioned For Growth
- Increasing incidence of eye diseases among all ages.
- Ophthalmic drugs patent cliff of $3B in next five years providing a significant growth opportunity for generic versions.
- Canadian ophthalmic segment has a 32.6% annual growth rate.
- Acquiring additional 70-100 ophthalmic drug products over the next 3 years.
Competitive Advantage
- Global market opportunity for generic ophthalmics exports
- Only four drug companies controlling the Canadian ophthalmics market
- Canadian ophthalmic drugs among the highest priced in the world
- Ophthalmic drugs have accelerated registration approvals as they do not require BA/BE studies to be done
Share Structure
59,359,131
Issued & Outstanding
65,112,776
Fully diluted common shares
5,753,645
Warrants & Options
Corporate Governance And Compensation Committee Charter
ViewStay In Touch
Trade Alert - Delivering the latest product trends and industry news straight to your inbox.
